Drugs / LNK01004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06553287 | Jul 2023 → Jun 2024 | atopic eczema | Lynk Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07071610 | Mar → Jul 2025 | atopic eczema | Lynk Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNK01004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07071610 ↗ |
| Route | Topical | “LNK01004 ointment 0.3% for topical application” NCT06553287 ↗ |